Hosted on MSN1mon
Bio-Thera signs US deal with Intas for golimumab biosimilar
Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 in the US. Bio-Thera will develop ...
JD Supra1mon
Regulatory and Commercial Updates on Bio-Thera’s BAT2506 (golimumab)
Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. According to Bio-Thera, binding of golimumab to TNF-α results in ...
Verywell Health on MSN4mon
4 Types of Biologics Used for Ulcerative Colitis
Biologics are large-molecule medications created in a lab ... such as Humira (adalimumab), Simponi (golimumab), Remicade ...
The Victoria Advocate1mon
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
BAT2506, a tumor necrosis factor-alpha (TNF-alpha) blocker, is a Phase 3 biosimilar candidate to Simponi ® (golimumab) Agreement will provide Accord BioPharma with future U.S. commercialization ...
Nasdaq1mon
FDA To Review Alvotech/Teva's BLA For AVT05, The 1st Biosimilar To Golimumab
AVT05 is a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions.